Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)
Status:
NOT_YET_RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
The usual first treatment for Pneumocystis jirovecii pneumonia (PCP) is an antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX). However, some patients cannot take this medication because of allergies, side effects, or lack of response.
This study asks the question:
When TMP-SMX cannot be used, which alternative treatment for PCP provides the best balance of effectiveness and safety?
Phase:
PHASE4
Details
Lead Sponsor:
McGill University Health Centre/Research Institute of the McGill University Health Centre